Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio C Chavez

Showing results (61-70 of 132) with videos related to

Pageof 14
Sort By:
Blood Neoplasia|January 15, 2026
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomasJulio C Chavez, Ellen Napier, Attilio Bondanza, et al.
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Nature Reviews. Clinical Oncology|November 2, 2024
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemiaMichele D Stanchina, Skye Montoya, Alexey V Danilov, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
The American Journal of Cardiology|June 19, 2019
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic ChemotherapyMichael G Fradley, Matthew Gliksman, Josephine Emole, et al.
Transplantation and Cellular Therapy|August 15, 2022
Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell TherapyDasom Lee, Aryanna I Jordan, Meghan A Menges, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Cancer|November 14, 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphomaDaniel J Landsburg, Adam M Petrich, Jeremy S Abramson, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Pageof 14

Showing results (61-70 of 132) with videos related to

Sort By:
Pageof 14
Blood Neoplasia|January 15, 2026
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomasJulio C Chavez, Ellen Napier, Attilio Bondanza, et al.
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Nature Reviews. Clinical Oncology|November 2, 2024
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemiaMichele D Stanchina, Skye Montoya, Alexey V Danilov, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
The American Journal of Cardiology|June 19, 2019
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic ChemotherapyMichael G Fradley, Matthew Gliksman, Josephine Emole, et al.
Transplantation and Cellular Therapy|August 15, 2022
Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell TherapyDasom Lee, Aryanna I Jordan, Meghan A Menges, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Cancer|November 14, 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphomaDaniel J Landsburg, Adam M Petrich, Jeremy S Abramson, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Pageof 14